Biochemical and biophysical research communications · 2025
Nintedanib inhibits neovascularization and subretinal fibrosis in a laser-induced choroidal neovascularization mouse model.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qin Shiyue, Zhu Yingying, Liu Yinping, Xie Hai, Zhang Jingfa, Zhang Chaoyang, Xu Guoxu
Аннотация
BACKGROUND: Subretinal fibrosis is a pivotal pathological factor contributing to vision loss in the elderly with neovascular age-related macular degeneration (nAMD), which is lack of effective treatment currently. The aim of this study was to assess the effects of nintedanib on subretinal fibrosis in a laser-induced choroidal neovascularization (CNV) mouse model and elucidate the molecular mechanisms of its action.
METHODS: The CNV mouse model was established by laser photocoagulation, and nintedanib was administered intravitreally 1 day after laser induction to verify the therapeutic efficacy of nintedanib on mice. TGF-β1 was employed to induce epithelial-mesenchymal transition (EMT) in ARPE-19 cells. Subsequently, immunofluorescence, transwell migration, scratch assay and Western blot were employed to assess the effect of nintedanib on subretinal fibrosis, EMT and EMT-associated cell function.
RESULTS: The neovascular and fibrotic lesions exhibited a significant reduction in laser-induced CNV mice on days 7 and 14 after intravitreal injection of various concentrations of nintedanib. Compared to normal control mice, the expression of fibrosis markers (collagen-1, α-SMA and fibronectin) was significantly upregulated in the RPE-choroid-sclera complexes of CNV mice, which was effectively attenuated by nintedanib. Furthermore, following nintedanib treatment, the TGF-β1-induced EMT of the ARPE-19 cells was significantly inhibited, as evidenced by a reduction in the levels of collagen-1, α-SMA, fibronectin, Vimentin and N-cadherin, along with a diminished capacity for cell migration. Mechanistically, nintedanib effectively blocked the activation of Smad 2/3, ERK 1/2, p38 and Akt signaling pathways in ARPE-19 cells induced by TGF-β1.
CONCLUSION: The inhibition of subretinal fibrosis by nintedanib might be attributed to its suppression of EMT via inactivation of the Smad 2/3, ERK 1/2, p38 and Akt signaling pathways, thereby providing a potential molecule for the treatment of subretinal fibrosis.
METHODS: The CNV mouse model was established by laser photocoagulation, and nintedanib was administered intravitreally 1 day after laser induction to verify the therapeutic efficacy of nintedanib on mice. TGF-β1 was employed to induce epithelial-mesenchymal transition (EMT) in ARPE-19 cells. Subsequently, immunofluorescence, transwell migration, scratch assay and Western blot were employed to assess the effect of nintedanib on subretinal fibrosis, EMT and EMT-associated cell function.
RESULTS: The neovascular and fibrotic lesions exhibited a significant reduction in laser-induced CNV mice on days 7 and 14 after intravitreal injection of various concentrations of nintedanib. Compared to normal control mice, the expression of fibrosis markers (collagen-1, α-SMA and fibronectin) was significantly upregulated in the RPE-choroid-sclera complexes of CNV mice, which was effectively attenuated by nintedanib. Furthermore, following nintedanib treatment, the TGF-β1-induced EMT of the ARPE-19 cells was significantly inhibited, as evidenced by a reduction in the levels of collagen-1, α-SMA, fibronectin, Vimentin and N-cadherin, along with a diminished capacity for cell migration. Mechanistically, nintedanib effectively blocked the activation of Smad 2/3, ERK 1/2, p38 and Akt signaling pathways in ARPE-19 cells induced by TGF-β1.
CONCLUSION: The inhibition of subretinal fibrosis by nintedanib might be attributed to its suppression of EMT via inactivation of the Smad 2/3, ERK 1/2, p38 and Akt signaling pathways, thereby providing a potential molecule for the treatment of subretinal fibrosis.